Metastatic extramammary Paget's disease responding to weekly paclitaxel

Vania Phuoc, Axel Grothey

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Metastatic extramammary Paget's disease (EMPD) is a rare cancer with no validated systemic treatment. Regimens including FECOM 5-fluorouracil (5-FU, epirubicin, carboplatin, vincristine and mitomycin C), 5-FU/cisplatin and single agent docetaxel exhibited varying levels of efficacy in case reports. A 58-year-old man with EMPD diffusely metastatic to bone presented with worsening shortness of breath, significant pancytopenia and disseminated intravascular coagulation (DIC). He was started on low-dose heparin for the DIC and weekly paclitaxel. Initially requiring almost daily transfusions, his shortness of breath improved after two doses of paclitaxel, and he became transfusionindependent after only three doses. Correlating with his disease course, the patient's prepaclitaxel carcinoembryonic antigen level of 62.1 ng/mL decreased to 7.4 ng/mL on 3-month follow-up, and he showed no progression of disease on imaging. With no validated chemotherapy regimen currently, this case can help guide consideration of paclitaxel in future treatment of metastatic EMPD.

Original languageEnglish (US)
Article numberA604
JournalBMJ case reports
StatePublished - Apr 22 2015

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Metastatic extramammary Paget's disease responding to weekly paclitaxel'. Together they form a unique fingerprint.

Cite this